American Century Companies Inc. Reduces Holdings in Evolent Health, Inc. (NYSE:EVH)

American Century Companies Inc. cut its position in Evolent Health, Inc. (NYSE:EVH) by 15.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,313,504 shares of the technology company’s stock after selling 246,640 shares during the quarter. American Century Companies Inc. owned 1.13% of Evolent Health worth $25,114,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in EVH. NBC Securities Inc. boosted its position in Evolent Health by 16.6% in the 1st quarter. NBC Securities Inc. now owns 2,461 shares of the technology company’s stock valued at $81,000 after buying an additional 350 shares during the last quarter. Principal Financial Group Inc. boosted its stake in Evolent Health by 3.2% during the 2nd quarter. Principal Financial Group Inc. now owns 15,594 shares of the technology company’s stock valued at $298,000 after acquiring an additional 480 shares during the last quarter. Ascent Group LLC grew its holdings in Evolent Health by 2.8% during the 1st quarter. Ascent Group LLC now owns 20,330 shares of the technology company’s stock worth $667,000 after acquiring an additional 550 shares in the last quarter. SeaCrest Wealth Management LLC increased its position in shares of Evolent Health by 6.3% in the 2nd quarter. SeaCrest Wealth Management LLC now owns 10,200 shares of the technology company’s stock worth $195,000 after purchasing an additional 600 shares during the last quarter. Finally, American International Group Inc. raised its stake in shares of Evolent Health by 1.2% in the 1st quarter. American International Group Inc. now owns 55,402 shares of the technology company’s stock valued at $1,817,000 after purchasing an additional 640 shares in the last quarter.

Insider Transactions at Evolent Health

In related news, President Daniel Joseph Mccarthy sold 23,693 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $30.89, for a total transaction of $731,876.77. Following the sale, the president now owns 198,809 shares of the company’s stock, valued at $6,141,210.01. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CEO Seth Blackley sold 187,904 shares of Evolent Health stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total value of $5,637,120.00. Following the transaction, the chief executive officer now owns 411,924 shares of the company’s stock, valued at approximately $12,357,720. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Daniel Joseph Mccarthy sold 23,693 shares of the stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $30.89, for a total transaction of $731,876.77. Following the sale, the president now directly owns 198,809 shares of the company’s stock, valued at $6,141,210.01. The disclosure for this sale can be found here. In the last three months, insiders sold 307,291 shares of company stock valued at $9,290,385. Company insiders own 1.60% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on EVH shares. JMP Securities lowered their price objective on Evolent Health from $34.00 to $31.00 and set a “market outperform” rating for the company in a report on Friday, August 9th. Stephens reissued an “overweight” rating and set a $42.00 price target on shares of Evolent Health in a research report on Tuesday, July 30th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $42.00 price objective on shares of Evolent Health in a report on Monday, August 26th. Truist Financial reissued a “buy” rating and set a $33.00 target price on shares of Evolent Health in a report on Tuesday, August 27th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Evolent Health from $36.00 to $45.00 and gave the company an “overweight” rating in a report on Monday, August 19th. One analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $40.40.

Evolent Health Trading Up 0.9 %

Shares of EVH stock opened at $30.82 on Thursday. Evolent Health, Inc. has a 1 year low of $17.98 and a 1 year high of $35.00. The firm has a market capitalization of $3.58 billion, a PE ratio of -24.67 and a beta of 1.57. The stock has a fifty day moving average of $25.98 and a two-hundred day moving average of $26.43. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.08 and a current ratio of 1.08.

Evolent Health (NYSE:EVH) last posted its quarterly earnings data on Thursday, August 8th. The technology company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.09. The business had revenue of $647.10 million during the quarter, compared to the consensus estimate of $636.46 million. Evolent Health had a negative net margin of 3.16% and a positive return on equity of 8.47%. The company’s quarterly revenue was up 37.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.06 earnings per share. As a group, research analysts expect that Evolent Health, Inc. will post 0.86 EPS for the current year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.